The Journal of Infectious Diseases · 2004 · 77 citations · 41 references
Life SciencesGeneticsMicrobiologyDiagnostic MicrobiologyMedical MicrobiologyMicrobial GeneticsPulmonary TuberculosisTuberculosis DiagnosisTuberculosis Diagnostic TestingDrug Resistance MutationsGenetic Heterogeneity AnalysisMolecular Drug ResistanceMycobacterium Tuberculosis InfectionResistance-associated MutationsRestriction Fragment Length Polymorphism AnalysisTuberculosis Drug ResistanceTuberculosis Molecular Testing
Multidrug-resistant tuberculosis (MDR-TB) is a major public health problem because treatment is complicated, cure rates are well below those for drug-susceptible tuberculosis (TB), and patients may remain infectious for months or years, despite receiving the best available therapy. To gain a better understanding of MDR-TB, we characterized serial isolates recovered from 13 human immunodeficiency virus-negative patients with MDR-TB, by use of IS6110 restriction fragment-length polymorphism analysis, spacer oligonucleotide genotyping (i.e., "spoligotyping"), and sequencing of rpoB, katG, mabA-inhA (including promoter), pncA, embB, rpsL, rrs, and gyrA. For all 13 patients, chronic MDR-TB was caused by a single strain of Mycobacterium tuberculosis; 8 (62%) of the 13 strains identified as the cause of MDR-TB belonged to the W-Beijing family. The sputum-derived isolates of 4 (31%) of the 13 patients had acquired additional drug-resistance mutations during the study. In these 4 patients, heterogeneous populations of bacilli with different resistance mutations, as well as mixtures of drug-susceptible and drug-resistant genotypes, were observed. This genetic heterogeneity may require treatment targeted at both drug-resistant and drug-susceptible phenotypes.
41
Global Trends in Resistance to Antituberculosis Drugs
Marcos Espinal, A László, Lone Simonsen et al. · New England Journal of Medicine · 2001 · 675 citations
Public Health, Infectious Disease Control, Infectious Diseases +17